Company Directory / research
PrivateFor profitresearchMilton, United Kingdom
Grey Wolf Therapeutics
First-of-its-kind antigen modulation to address immune dysfunction in oncology and autoimmunity
- Founded
- 2017 9 years ago
- Staff
- 11-50 band, as listed
- Followers
- - on LinkedIn
- Funding
- $122M as listed, currency not stated
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed
Age
9 years old.
Reach
Website ranked #4,258,156 in the world for traffic, about 2k visits a month.
What it does
BiotechnologyHealth CareTherapeutics
Funding, as listed
$122M currency not stated
- Rounds5
- LatestSeries b, May 2024
- Investors7, 5 leading
What the source datasets report. We have not watched these rounds ourselves.
Funding filed with regulators
Grey Wolf Therapeutics filed 3 raises, $80M in all. Filings say how much was sold and to how many investors; they never name the investors.
- Jan 2023$36MUK share allotment
- Dec 2021$39MUK share allotment
- Oct 2021$4.9MUK share allotment
Every detail we hold
Everything the source datasets list about Grey Wolf Therapeutics, field by field. Contact details are held but never shown.
The company
- Name
- Grey Wolf Therapeutics
- Type
- For profit
- Status
- Private
- Founded
- 2017
- Founders
- Peter Joyce, Tom McCarthy
- Industry
- research
- Categories
- Biotechnology, Health Care, Therapeutics
Where
- City
- Milton
- Country
- United Kingdom
- Markets
- Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 11-50
- Web traffic rank
- #4,258,156
- Monthly web visits
- 2,317
Funding, as listed
- Total
- 122,311,549 (currency not stated)
- Rounds
- 5
- Latest round
- Series b
- Latest round date
- May 2024
- Investors
- 7
- Lead investors
- 5
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Grey Wolf Therapeutics raised €46 million in a Series B round to develop disease-modifying therapies for autoimmune disorders. Additionally, the company closed an oversubscribed $50 million Series B financing led by ICG Life Sciences Team to accelerate and expand its antigen modulation technology.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in United Kingdom.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 372,993 companies in United Kingdom and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.